• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Disease categories and therapies » Inflammatory

Inflammatory
Inflammatory RSS Feed RSS

Théa ends deal with Olix, returns rights of ocular drugs

June 25, 2024
By Marian (YoonJee) Chu
France’s Théa Open Innovation, a subsidiary of Laboratoires Théa SAS, terminated its licensing agreement with South Korea’s Olix Pharmaceuticals Inc., and returned global rights of Olix’s ocular small interfering RNA (siRNA) biologic agents, OLX-301D and OLX-301A.
Read More
Deal handshake with coin, chart background

Aprilbio, Evommune strike $475M deal for autoinflammatory drug

June 25, 2024
By Marian (YoonJee) Chu
Aprilbio Co. Ltd. saw its stock surge 30% June 20 after announcing a potential $475 million (₩655.88 billion) deal with Evommune Inc. for autoimmune disease drug candidate APB-R3.
Read More
Sunrise in a desert with sand dunes
Inflammatory

Study gives insight into five inflammatory diseases, and the noncoding genome

June 25, 2024
By Anette Breindl
A recent paper has identified the enhancer ETS2, located in a so-called gene desert, as a contributor to five separate immune disorders. It also showed that one of ETS2’s target genes mediating this inflammation was the eminently druggable MEK, a kinase that is the target of the FDA-approved inhibitors Mekinist (trametinib, GSK plc), Mektovi (binimetinib, Array Biopharma Inc.), Cotellic (cobimetinib, Roche Holding AG) and Koselugo (selumetinib, Astrazeneca plc/Merck & Co. Inc.).
Read More

Théa ends deal with Olix, returns rights of ocular drugs

June 24, 2024
By Marian (YoonJee) Chu
France’s Théa Open Innovation, a subsidiary of Laboratoires Théa SAS, terminated its licensing agreement with South Korea’s Olix Pharmaceuticals Inc., and returned global rights of Olix’s ocular small interfering RNA (siRNA) biologic agents, OLX-301D and OLX-301A.
Read More
Blood cells and bacteria

Broader sepsis insights gleaned from SARS-CoV-2-driven research

June 24, 2024
By Nuala Moran
New research has pinpointed gene signatures that determine what immune responses will be activated in the development of sepsis, pointing to novel targets and opening the way for the stratification of clinical trials and for patients to be treated on the basis of their immune response, rather than their symptoms.
Read More
Deal handshake with coin, chart background

Aprilbio, Evommune strike $475M deal for autoinflammatory drug

June 21, 2024
By Marian (YoonJee) Chu
Aprilbio Co. Ltd. saw its stock surge 30% June 20 after announcing a potential $475 million (₩655.88 billion) deal with Evommune Inc. for autoimmune disease drug candidate APB-R3.
Read More
Neutrophil and red blood cells
Inflammatory

Alivexis and Melodia sign license agreement for cathepsin C inhibitor MDI-0151

June 21, 2024
Alivexis Inc. and Melodia Therapeutics AG have entered into an exclusive license agreement for the worldwide development, manufacturing and commercialization of Alivexis’ MDI-0151, a novel cathepsin C inhibitor identified in Alivexis’ MOD-A discovery program.
Read More
Liver anatomy with virus
Gastrointestinal

Ose reports preclinical results on IL-35 mRNA therapeutic for autoimmune hepatitis

June 21, 2024
Ose Immunotherapeutics SA has presented preclinical data on its mRNA therapeutic platform for the treatment of inflammatory and autoimmune disorders. The platform has been designed for the local delivery of mRNA into inflammatory tissue using lipid nanoparticles (LNPs). Interleukin-35 (IL-35) has been shown in preclinical studies to have a key role in controlling several immune-related disorders, including autoimmune diseases.
Read More
Blood cells and bacteria
Infection

Broader sepsis insights gleaned from SARS-CoV-2-driven research

June 21, 2024
By Nuala Moran
New research has pinpointed gene signatures that determine what immune responses will be activated in the development of sepsis, pointing to novel targets and opening the way for the stratification of clinical trials and for patients to be treated on the basis of their immune response, rather than their symptoms.
Read More
Inflammatory

Odyssey Therapeutics discovers new RIPK2 inhibitors

June 19, 2024
Odyssey Therapeutics Inc. has described receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of autoimmune diseases, chronic granulomatous disease, neurodegeneration, inflammatory disorders and cancer.
Read More
Previous 1 2 … 21 22 23 24 25 26 27 28 29 … 102 103 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe